Showing 5961-5970 of 9948 results for "".
- Spotlight On: Honey and Its Role in Wound Healinghttps://practicaldermatology.com/news/spotlight-on-honey/2461353/Honey may play a role in wound healing due to its antimicrobial and tissue-regenerative properties, according to scientists from the University of Manchester. Their review of more than 250 articles spans 85 years -with oldest article from 1937- is published in the journal Pharmaceu
- Positive Dupixent Phase 3 Data in Children Aged 6 Months to 5 Years with Moderate-to-severe ADhttps://practicaldermatology.com/news/positive-dupixent-phase-3-data-in-children-aged-6-months-to-5-years-with-moderate-to-severe-ad/2461349/Dupixent significantly improved skin clearance, and reduced itch and overall disease severity in children as young as 6 months old, according to a new Phase 3 trial in the Lancet. Thes
- Almirall's Tildrakizumab Demonstrates Meaningful Sleep Improvement in People Living with Psoriasishttps://practicaldermatology.com/news/almiralls-tildrakizumab-demonstrates-meaningful-sleep-improvement-in-people-living-with-psoriasis/2461345/During the 31st EADV (European Association of Dermatology and Venereology) Congress, Almirall S.A shared the results from TRIBUTE, an interventional phase IV clinical study that resembled real-life clinical practice. In this study, Ilumetri (tildrakizumab) is&n
- Meet the Cast of Allergan Aesthetics and BOTOX Cosmetic's New 'See Yourself' Campaignhttps://practicaldermatology.com/news/meet-the-cast-of-allergan-aesthetics-and-botox-cosmetics-new-see-yourself-campaign/2461344/Allergan Aesthetics is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX Cosmetic 'See Yourself' campaign. A After receiving nearly 20,000 submis
- FDA Approves BMS' Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-bms-sotyktu-for-plaque-psoriasis/2461341/The FDA has approved Bristol Myers Squibb Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recom
- EADV News: ‘Healthy’ Suntan Myths Persist in Europehttps://practicaldermatology.com/news/eadv-news-healthy-suntan-myths-persist-in-europe/2461338/Fully eight in 10 Europeans believe tans are attractive with almost as many (73%) saying tans are healthy, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. Results from a survey, conducted by La Roche-Posay Laboratoires and
- Sklip Gets Approval to Test Skin Cancer Triage at Home Using AIhttps://practicaldermatology.com/news/sklip-gets-approval-to-test-skin-cancer-triage-at-home-using-ai/2461336/Sklip System AI for safe, effective and regulated consumer use
- DREAM Initiative from Allergan Aesthetics, SkinBetter Science Launches CARE Curriculumhttps://practicaldermatology.com/news/dream-initiative-from-allergan-skinbetter-science-launches-care-curriculum/2461334/The DREAM Initiative®, developed by Allergan Aesthetics and skinbetter science®, has supported the development of a racial equity curriculum for dermatology residency programs. The Curriculum f
- Allergan Aesthetics Hits Milestone: 100 Million Syringes of JUVÉDERM Shippedhttps://practicaldermatology.com/news/allergan-aesthetics-hits-milestone-100-million-syringes-of-juvederm-shipped/2461330/Drumroll, please…Allergan Aesthetics, an AbbVie company has produced and shipped 100 million syringes of JUVÉDERM products globally. Since its launch in 2000, the JUVÉDERM Collection of Fillers has grown to where its products are now avail
- EADV News: Tape Strip Test May Predict Eczema Risk in Babieshttps://practicaldermatology.com/news/eadv-news-tape-strip-test-may-predict-eczema-risk-in-babies/2461329/An immune biomarker in newborns may predict the subsequent onset and severity of paediatric atopic eczema, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. The Barrier dysfunction in Atopic newBorns (BABY) study analyzed a c